Novel RT-PCR Using Sugar Chain-Immobilized Gold-Nanoparticles Correlates Patients’ Symptoms: The Follow-Up Study of COVID-19 Hospitalized Patients

Author:

Kajiya TakashiORCID,Sawayama Hayate,Arima Eriko,Okamoto Mika,Baba Masanori,Toyama Masaaki,Okuya KosukeORCID,Ozawa MakotoORCID,Atsuchi Nobuhiko,Nishi Junichiro,Suda Yasuo

Abstract

Background: The transmissible capacity and toxicity of SARS-CoV-2 variants are continually changing. We report here the follow-up study of hospitalized COVID-19 patients from 2020 to 2022. It is known that the PCR diagnosis for hospitalized patients sometimes causes confusion because of the incompatibility between their diagnosis and symptoms. We applied our sugar chain-immobilized gold-nanoparticles for the extraction and partial purification of RNA from specimens for quantitative RT-PCR assay and evaluated whether the results correlate with patients’ symptoms. Methods and Results: Saliva specimens were taken from hospitalized patients with mild or moderate symptoms every early morning. At the time of RT-PCR diagnosis, two methods for the extraction and partial purification of RNA from the specimen were performed: a commonly used Boom (Qiagen) method and our original sugar chain-immobilized gold nanoparticle (SGNP) method. For symptoms, body temperature and oxygen saturation (SpO2) of patients were monitored every 4 h. Conclusions: It was clear that patients infected with the Delta variant needed more time to recover than those with the Omicron variant, and that the SGNP method showed more realistic correlation with the symptoms of patients compared with the common Qiagen method.

Funder

Japan Agency for Medical Research and Development

Kagoshima University

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference24 articles.

1. (2022, June 10). Situation Report on COVID-19, Ministry of Health, Labour and Welfare, Japan. Available online: https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou_00006.html.

2. (2022, May 22). COVID Data Tracker Weekly Review, Centers for Disease Control and Prevention, Available online: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html.

3. An interactive web-based dashboard to track COVID-19 in real time;Lancet,2020

4. (2022, May 22). COVID-19 Dashboard, Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6.

5. (2022, May 22). From Alpha to Omicron: Everything You Need to Know about SARS-CoV-2 Variants of Concern, Gavi, the Vaccine Alliance. Available online: https://www.gavi.org/vaccineswork/alpha-omicron-everything-you-need-know-about-coronavirus-variants-concern.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Gold nanoparticle-based strategies against SARS-CoV-2: A review;REVIEWS ON ADVANCED MATERIALS SCIENCE;2023-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3